This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Medical device companies that leverage today’s technology to better share and track product and safety information will outpace rivals and gain a competitive edge. They will be the innovators that can solve problems faster and streamline their workflows for optimal efficiency.
Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies.
Fighting for a place in the competitive atopic dermatitis market, Incyte hopes to reach younger patients with its JAK inhibitor cream Opzelura. Fighting for a place in the competitive atopic dermatitis market, Incyte hopes to reach young patients with its JAK inhibitor cream Opzelura.
With a phase 3 miss following a fatality in a related study and marking what analysts are calling the “final nail” in Pfizer’s Duchenne muscular dystrophy (DMD) gene therapy coffin, Sarepta Therape | With a phase 3 miss and severe safety signals, Pfizer's Duchenne muscular dystrophy gene therapy candidate is no competition to Sarepta's established (..)
But increased competition is on the horizon. Tentative approval means Lumryz has satisfied all the FDA requirements for efficacy, safety, and quality standards, but it can’t be fully approved until a patent or other exclusivity expires. Competition starts to heat up. Classic treatment options. Two decades of exclusivity.
Thus, LY03010 could be more convenient to administer and improve patient compliance by optimising the initial dosing regimen, while ensuring efficacy and safety. The post Promising schizophrenia drug faces tough competition appeared first on European Pharmaceutical Review.
Award-winning health and wellness advertising agency AbelsonTaylor Group received the inaugural ACE Aspire Award for its employee Psychological Safety Initiative from the Healthcare Businesswomen’s Association (HBA). In 2022, AbelsonTaylor developed and implemented a large-scale, ongoing Psychological Safety initiative for its 300 employees.
Compendial testing covers a wide array of materials, subjects, and locations designed to create standards and programs that ensure the quality and safety of approved articles for a geographical location or areas such as USP (For the United States market) or Ph Eur (For European markets).
We need a 21st-century approach that puts patient safety first. In other words, money over safety. Ironically, in later times, the intense competition for out-of-patent drugs has subsided, which has led to spiraling rises in generic drug prices and shortages. Up to 90% of drugs now sold in the US and UK are generic.
Drug pricing is done by internal teams who look at what the market will bear and the competitive landscape. 3hree: DTC marketing minimizes the side effects of prescription drugs – One of the top pages within prescription drug websites continues to be “safety information.”
In the highly competitive pharmaceutical industry, your brand’s visibility plays a crucial role, i.e., it can make or break your market success. With the right strategies, you can boost your visibility and regain your competitive edge. With the right strategies, you can boost your visibility and regain your competitive edge.
This dual-layer certification process can create significant delays, as each framework involves extensive assessments for safety and performance under separate requirements specific to medical device and AI-specific criteria.
Table of Contents Sr# Headings 1 Introduction 2 Understanding Pharma Marketing 3 Key Pharma Marketing Strategies 4 Embracing Digital Transformation 5 Building Trust with HCPs 6 Conclusion Introduction In the pharma industry, marketing isnt just about selling; its about creating value in an ultra-competitive space.
Companies need to carefully assess the value of the assets being acquired or licensed, considering factors such as the stage of development, market potential, the competitive landscape and intellectual property protection.
billion, so biosimilar competition could significantly expand patient access to this biologic therapy within the fields of gastroenterology, dermatology, and rheumatology, according to STADA and Alvotech. The EU ustekinumab market is worth €2.5 In this region, STADA already has six biosimilars approved in this market.
This has resulted in “increased competition and price pressure, driving the growth of the biosimilar market”. The latter of which is important in “gaining a competitive advantage”, the author noted. However, with greater availability of safety and efficacy data, this is also expected to help expand the market, the report stated.
But how do you make your campaigns stand out in such a highly regulated and competitive industry? For example, an ad for Humira should clearly outline potential benefits and direct users to full safety information. Being proactive will give you a competitive edge. Keep an eye on trends like voice search and AI-driven content.
An open-label pharmacokinetic and safety study of LY03004 evaluated an escalating single intramuscular injection in stable patients with schizophrenia or schizoaffective disorder. So, Rykindo ® will have to contend with the competition of other antipsychotic LAIs as treatments for psychosis disorders.
billion buyout of Principia Biopharma has run into trouble, after the FDA placed it on partial clinical hold while a safety signal is investigated. Those changes haven’t been enough to prevent the FDA from taking action, although outside the US the studies will continue as planned with the tighter safety monitoring.
For pharma marketing executives and their teams, staying current helps maintain competitive advantage, ensures compliance, and unlocks opportunities for smarter, faster campaign decisions. These platforms can also monitor FDA press releases, brand safety incidents, and healthcare policy changes in real time.
When developing content for new drug labels, life sciences companies’ regulatory teams face challenges in gathering intelligence to better understand competitive factors, market dynamics, and effective approval strategies. Understanding patient sub-group exceptions for competitive or for label development purposes.
The move further expands and integrates drug toxicity data and translational safety intelligence from OFF-X into all aspects of the life science cycle. OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery Intelligence and Cortellis Competitive Intelligence.
Pharma marketing executives face unique challenges like regulatory restrictions, stiff competition, and shifting consumer expectations. Highlight topics like disease awareness, drug safety, and lifestyle tips to add value to your audience. So, how can you build trust, boost brand awareness, and still drive sales?
Since then, the ophthalmology division has suffered some setbacks, not least the disappointing performance Lucentis follow-up Beovu (brolucizumab), which had been billed as a successor to Lucentis, but has seen its growth pegged back by safety issues. billion in the first nine months of this year.
The FDA said its approval of Wezlana is based on “a comprehensive review of scientific evidence demonstrating it is highly similar to Stelara and that there are no clinically meaningful differences between the two products in terms of safety, purity and potency.” Sustainable biosimilar competition in Europe: can it be achieved?
Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe. But from a safety point of view, observational studies can be more representative of the population the drug will serve.
But how does it work, and how can you make the most of it in the competitive pharmaceutical industry? Example: When advertising a drug like Lyrica , your ad must state potential side effects and direct users to detailed safety information. Use dynamic ad formats, and always emphasize the benefits and safety profile of the drug.
It could be superior efficacy, a better safety profile, or more affordable pricing. First, ensure your product’s market entry strategy is carefully planned, taking into account the competitive landscape, pricing, distribution, and regulatory approvals. Create an Effective Launch Strategy A successful launch is a phased process.
Competitive Keywords: Terms related to rival brands, helping capture market share. Avoiding misleading claims that exaggerate efficacy or safety. Pharma marketers who embrace PPCs precision targeting will gain a competitive edge in reaching healthcare professionals effectively.
Brand managers use GVD assets across multiple regulatory and strategic deliverables, including data summaries for efficacy, safety, and cost-effectiveness that feed health technology assessments. SLRs aim to answer specific questions related to drug safety, efficacy, and comparative effectiveness, often contributing to GVDs.
As for its benefits in pharmacovigilance, the paper explained that GAMP 5 “helps organisations maintain high-quality standards in adverse event reporting and analysis, ensuring the safety of patients and the integrity of data. GAMP 5 update: computerized system expectations for pharma manufacturers Benefits of Pharma 4.0
But in an industry with strict regulations, high competition, and complex audience needs , landing page optimization for pharmaceutical brands requires a strategic and compliant approach. By prioritizing compliance, transparency, and patient safety , pharma brands can avoid ad disapprovals and regulatory fines.
Research gathered from real-world settings offers invaluable insights into drug efficacy, safety, and patient preferences. In a competitive landscape, leveraging research is the smartest way to connect with patients and providers alike. Marketers can use RWE to craft messages that resonate with both healthcare providers and patients.
The management of SLE and LN consists largely of treatment options that are based on highly efficacious steroids or immune-suppressive therapy with an undesirable safety profile, which includes accrued organ damage, infections and cancer.
PM360 spoke to Kokino about the evolution of the biosimilars market from its nascent days, why the now increased competition within the market is causing some companies to reconsider developing biosimilars, what to look for over the next few years, and how Accord’s approach is a bit different from what other companies are doing.
The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population. million for Hemgenix [AAV5-hFIX-Padua]). Proprietary cell lines also allow companies to attain IP and build brand recognition.
Increased trafficking of illegal fentanyl represents a new threat to public health and safety. Fentanyl’s addictive properties mean that a) a consumer’s addiction will overpower any safety concerns they may have, and b) the drug can secure more addicts than it kills. A lethal drug that creates its own demand. A dangerous future.
Side-effect data from the open-label studies was also encouraging, helping to downplay concerns abut evenamide’s cardiovascular and central nervous system safety that emerged in 2019. ” The new data could accelerate partnering efforts of the drug this year.
The UK Government has announced funding worth more than $894.6m (£800m) to back research into ground-breaking, experimental therapies and progress the response of the country to patient safety challenges. These research centres comprise a new facility in Exeter.
Simply adding more people to the team won’t deliver the scalability and dividends you’re looking for if your sales leaders aren’t willing to put in the work to create a culture of safety and empowerment that inspires confidence, continual development and genuine human connections. Developing Stellar Sales Leadership Skills.
Continuous learning and skill development are essential for maintaining a competitive edge in the dynamic field of medical device sales. Regulatory Considerations Medical device marketing using VR must adhere to regulatory guidelines and standards to ensure patient safety and compliance.
Key concerns for participants include safety and health, the time and effort required and a lack of job flexibility. Carried out online in 2022, 1,049 people responded to the survey. The results identified financial payment as the most popular motivation for taking part in clinical studies.
So there’s a piece of capital equipment that either myself or a clinical specialist is in charge of running and we also have a lot of, you know, feedback and input within the procedure in terms of where those probes should be placed and keeping in, you know, within the parameters of safety and efficacy for that patient.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content